We conducted a randomized controlled trial in 40 subjects with early T2D who received the GLP-1 analog exenatide ( n = 14 ) , the dipeptidyl peptidase IV inhibitor sitagliptin ( n = 12 ) , or the sulfonylurea glimepiride ( n = 14 ) as an active comparator insulin secretagogue for 6 months .